docetaxel anhydrous has been researched along with palbociclib in 6 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (palbociclib) | Trials (palbociclib) | Recent Studies (post-2010) (palbociclib) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 911 | 126 | 864 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | palbociclib (IC50) |
|---|---|---|---|
| Chain B, Cell division protein kinase 6 | Homo sapiens (human) | 0.015 | |
| Chain B, Cell division protein kinase 6 | Homo sapiens (human) | 0.015 | |
| Cyclin-T1 | Homo sapiens (human) | 1.5085 | |
| Cyclin-K | Homo sapiens (human) | 1.207 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 9.8 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.0109 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 9.8 | |
| Cyclin-A2 | Homo sapiens (human) | 2.2042 | |
| Acetylcholinesterase | Mus musculus (house mouse) | 0.021 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.0115 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 9.15 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 4.1887 | |
| G1/S-specific cyclin-D2 | Homo sapiens (human) | 0.0127 | |
| G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.0194 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 3.48 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 1.1821 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 0.0631 | |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | 0.018 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Ajenjo, N; Albarrán, MI; Bischoff, JR; Blanco-Aparicio, C; Cebriá, A; Cebrián, D; Cuadrado-Urbano, M; García, AB; García-Serelde, B; Gómez de la Oliva, CA; Gómez-Casero, E; González Cantalapiedra, E; Hernández, AI; Klett, J; Martínez-González, S; Oyarzabal, J; Pastor, J; Rabal, O; Rodríguez-Arístegui, S; Varela, C | 1 |
| Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
| Anderes, K; Arango, ME; Painter, CL; Yan, Z; Zhang, C | 1 |
| Bagante, F; Connolly, R; Pawlik, TM; Spolverato, G; Vitale, A | 1 |
| Brunken, L; Hassan, N; Jackson, J; Mellor, C; Mitchell, E; Ng'andu, K; O'Brien, A; Paus, R; Purba, TS; Shahmalak, A; Smart, E | 1 |
6 other study(ies) available for docetaxel anhydrous and palbociclib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Pyridazines; Quinolines; Structure-Activity Relationship; Triazoles | 2019 |
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
Advancing bioluminescence imaging technology for the evaluation of anticancer agents in the MDA-MB-435-HAL-Luc mammary fat pad and subrenal capsule tumor models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Line, Tumor; Docetaxel; Female; Humans; Kidney; Luminescent Proteins; Lung Neoplasms; Mammary Glands, Human; Mice; Mice, Nude; Mice, SCID; Neoplasm Transplantation; Neoplasms, Experimental; Piperazines; Pyridines; Taxoids; Xenograft Model Antitumor Assays | 2009 |
Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Hepatectomy; Humans; Letrozole; Liver Neoplasms; Male; Markov Chains; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Piperazines; Pyridines; Quality-Adjusted Life Years; Survival Rate; Taxoids; Triazoles | 2017 |
CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane-induced alopecia.
Topics: Alopecia; Antineoplastic Agents; Bridged-Ring Compounds; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Docetaxel; Humans; Keratinocytes; Models, Theoretical; Organ Culture Techniques; Paclitaxel; Piperazines; Protein Kinase Inhibitors; Pyridines; Stem Cells; Taxoids | 2019 |